AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled).

Claim 2 (previously presented): A pharmaceutical composition, wherein:

the composition comprises one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

Claim 3 (canceled).

Claim 4 (previously presented): The composition of Claim 2 wherein the dose units are in the form of discrete solid articles.

Claim 5 (currently amended): The composition of Claim 4 wherein the solid **articles** ~~**particles**~~ are tablets or capsules.

Claim 6 (previously presented): The composition of Claim 2 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

Claim 7 (original): The composition of Claim 6 wherein the substantially homogeneous flowable mass is a liquid suspension.

Claims 8-11 (canceled).

Claim 12 (previously presented): The composition of Claim 2 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

Claim 13 (previously presented): The composition of Claim 2 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

Claim 14 (original): The composition of Claim 13 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.

Claim 15 (original): The composition of Claim 14 comprising about 10 mg to about 1000 mg celecoxib in each dose unit.

Claims 16-18 (canceled).

Claim 19 (previously presented): A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, wherein:

the method comprises orally administering one or more dose units of a composition one to about six times a day;

the composition comprises a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

Claim 20 (previously presented): The method of Claim 19 wherein the medical condition or disorder is accompanied by acute pain.

Claim 21 (previously presented): The method of Claim 19 wherein the dose units are in the form of discrete solid articles.

Claim 22 (previously presented): The method of Claim 21 wherein the solid articles are tablets or capsules.

Claim 23 (previously presented): The method of Claim 19 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

Claim 24 (previously presented): The method of Claim 19 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

Claim 25 (previously presented): The method of Claim 19 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

Claim 26 (previously presented): A method of making a medicament useful in treatment or prophylaxis of a COX-2 mediated condition or disorder, wherein:

the method comprises incorporation of a selective cyclooxygenase-2 inhibitory drug of low water solubility into a pharmaceutical composition comprising one or more orally deliverable dose units, wherein the drug is in the form of solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

Claim 27 (previously presented): The method of Claim 26 wherein the dose units are in the form of discrete solid articles.

Claim 28 (previously presented): The method of Claim 27 wherein the solid articles are tablets or capsules

Claim 29 (previously presented): The method of Claim 25 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

Claim 30 (previously presented): The method of Claim 25 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position..

Claim 31 (previously presented): The method of Claim 25 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.